Clinical Trials
16 trialsNCT02231749 2026-05-27
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT03075423 2025-09-26
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
Goethe University
Phase 2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03297593 2025-06-06
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
Swiss Cancer Institute
Phase 2 Completed
NCT03138512 2024-12-18
CheckMate 914
Bristol-Myers Squibb
Phase 3 Completed
NCT03752398 2024-07-05
DUET-3
Xencor, Inc.
Phase 1 Completed
NCT03829111 2024-07-03
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
City of Hope Medical Center
Phase 1 Completed
NCT04518046 2024-06-05
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
Mirati Therapeutics Inc.
Phase 1 Completed
NCT03126331 2024-03-18
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02982954 2022-11-01
CHECKMATE 920
Bristol-Myers Squibb
Phase 4 Completed
NCT02917772 2022-10-06
TITAN-RCC
AIO-Studien-gGmbH
Phase 2 Completed
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT02089685 2022-09-13
MK-3475-029
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03029780 2022-06-29
CheckMate 800
Bristol-Myers Squibb
Phase 2 Completed
NCT01472081 2021-12-02
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
Phase 1 Completed
NCT00057889 2012-03-15
Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed